Humacyte, Inc. (HUMA)
NASDAQ: HUMA · Real-Time Price · USD
0.6655
-0.0220 (-3.20%)
Apr 21, 2026, 1:50 PM EDT - Market open
Humacyte Revenue
In the year 2025, Humacyte had annual revenue of $2.04M. Humacyte had revenue of $467.00K in the quarter ending December 31, 2025.
Revenue (ttm)
$2.04M
Revenue Growth
n/a
P/S Ratio
74.22
Revenue / Employee
$11,076
Employees
184
Market Cap
147.75M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.04M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 1.57M | 302.00K | 23.91% |
| Dec 31, 2021 | 1.26M | -228.00K | -15.29% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Agenus | 114.20M |
| Innate Pharma | 10.57M |
| Alpha Cognition | 10.22M |
| Fate Therapeutics | 6.65M |
| Oramed Pharmaceuticals | 2.00M |
| Connect Biopharma Holdings | 64.00K |
HUMA News
- 5 hours ago - Humacyte Announces Israeli Ministry of Health Acceptance of Marketing Authorization Application for Symvess® for Vascular Trauma Repair - GlobeNewsWire
- 8 days ago - Humacyte Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humacyte, Inc. - HUMA - Business Wire
- 11 days ago - Did Humacyte, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - PRNewsWire
- 25 days ago - Humacyte Announces Fourth Quarter and Year End 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 26 days ago - Humacyte Appoints Rick McElheny as Senior Vice President of Business Development - GlobeNewsWire
- 4 weeks ago - Humacyte To Announce 2025 Fourth Quarter and Year End Financial Results and Provide Business Update on March 27, 2026 - GlobeNewsWire
- 4 weeks ago - Humacyte, Inc. Announces Pricing of $20 Million Registered Direct Offering of Common Stock - GlobeNewsWire
- 5 weeks ago - Humacyte Submits Marketing Authorization Application for Symvess® in Israel for Vascular Trauma Repair - GlobeNewsWire